7/17 Taiwan Life Sciences Biweekly Newsletter2023-07-18
|Taiwan Life Sciences Biweekly|
|Chugai Pharma Taiwan Wins Asia Responsible Enterprise Awards for Two Consecutive Years - Initiates Various Environmental Sustainability Projects |
14 July, 2023
As a cutting-edge, innovative pharma company, Chugai Pharma Taiwan has won the Asia Responsible Enterprise Awards (AREA) once again this year in the Green Leadership category. Receiving the special award for two years in a row is a testament to the Company's outstanding performance in the field of social responsibility. Chugai Pharma Taiwan is committed to environmental sustainability, community engagement, and sustainable development. By hosting the innovative annual public welfare family day, the Company encourages its employees and their families to become involved and appreciate the magnificence of giving back to society. Furthermore, the Company has launched various short-term, medium-term, and long-term green campaigns. More... (in Chinese)
|Lotus Announces Zepzelca (lurbinectedin) Has Acquired TFDA Accelerated Approval for the Treatment of Metastatic Small Cell Lung Cancer |
12 July, 2023
Lotus Pharmaceutical (TW: 1795), a multinational pharmaceutical company, has announced that it has received accelerated approval from Taiwan Food and Drug Administration (TFDA) for ZEPZELCA (lurbinectedin), which is indicated for the treatment of adult metastatic small cell lung cancer (SCLC) patients with disease progression on or after platinum-based chemotherapy. The approval of ZEPZELCA marks a significant milestone for the company, marking Lotus' first licensed NCE oncology therapy to receive approval. The approval is based on the overall response rate and duration of response demonstrated in open-label monotherapy clinical trial. The TFDA grants accelerated approval designation in order to facilitate the development and expedite the review of applications for medicines to treat serious conditions that may fill critical unmet medical needs. More...
|Taiwan tops ranking in Numbeo's 'Global Health Care Index by Country' |
11 July, 2023
Taiwan ranked first in the world for the fifth consecutive year with a score of 85.9 in Numbeo's mid-year "Global Health Care Index by Country," per Liberty Times.
Numbeo, the world's largest database of user-contributed data about cities and countries, calculated a health score for each country based on technology, medical personnel qualifications, medical equipment, waiting times, accessibility of medical locations, and staff friendliness. A total of 4,119 cities were evaluated, with some 43,700 people participating in the survey. More...
|Memorandum of Understanding on Health Cooperation signed between Taiwan and the UK |
11 July, 2023
The relations between Taiwan and the UK have become closer and closer recently. To further strengthen health cooperation, a memorandum of understanding (MOU) on health cooperation between Taiwan and the UK was signed by Representative Kelly Wu-Chiao Hsieh of Taipei Representative Office in the UK and Representative John Dennis at the British Office Taipei on July 7, 2023. This MOU shows the strong partnership between Taiwan and the UK. More...
|TST Biomedical Electronics' medical devices granted US approval |
11 July, 2023
Quartz component manufacturer, Tai Saw Technology (TW: 3221), announced that its subsidiary, TST Biomedical Electronics' three medical devices had completed registration and listing under FDA Class I medical device regulations in the United States as in vitro diagnostics devices.
Among the three approved products, two are designed for the detection of metabolic and genetic cardiovascular disease risk factors, while the other is a form of quantitative analyzer. More... (in Chinese)
|EirGenix with high hopes for the launch of its breast cancer biosimilar drug in early 2024 |
10 July, 2023
EirGenix expects to respond to the FDA's deficient filing for the biosimilar EG12014 in July at the earliest, and if all goes well, there is still a chance that EG12014 will be approved in the fourth quarter and marketed in the first quarter of next year. EG1206A, a next-generation breast cancer drug, is also attracting attention. More...
|Taiwan attracts foreigners to come for reproductive medicine and cancer treatment |
6 July, 2023
Over the past three years, Taiwan's medical strength has not only been demonstrated in the prevention of the epidemic, but also in the proportion of people from Japan and ASEAN nations coming to Taiwan for international medical treatment. More than 10,000 came to Taiwan for 'baby-making' opportunities in the last three years. The medical sector believes that in addition to aesthetic and health check-ups, infertility and cancer treatment are among Taiwan's strengths, and that recovery from post-COVID-19 can be anticipated. More...
|Premier urges more US medical cooperation |
5 July, 2023
Taiwanese medical organizations should seek to improve cooperation with peers in the US, Premier Chen Chien-jen told a forum in Taipei on Monday. More...
|AnnJi Pharmaceutical raised NT$660M, 200 percent more than expected |
5 July, 2023
AnnJi Pharmaceutical said on June 30 that it had successfully completed a NT$660 million capital raising, demonstrating the market's recognition and support for the company. The actual subscription amount exceeded NT$960 million, reaching 200 percent of the original target of NT$480 million. More...
|Formosa Pharmaceuticals' NDA for postoperative eye inflammation and pain new drug to undergo review by the US FDA |
4 July, 2023
Formosa Pharmaceuticals (TW: 6838) announced that it had obtained notification from the US FDA that its new drug APP13007 for the treatment of postoperative eye inflammation and pain, had completed initial review of the new drug's preliminary NDA documents and would now proceed to the substantive review stage. More... (in Chinese)
|Panion & BF Biotech's new kidney drug approved as reimbursable drug in South Korea |
4 July, 2023
Panion & BF Biotech (TW: 1760) announced that its kidney new drug Nephoxil had received official approval in early July from South Korea's National Health Insurance (NHI) as a reimbursable drug. This comes after the drug obtained import marketing authorization through the company's authorized distribution partner, KKKR (Korea Kyungdong Pharmaceutical Co., Ltd.), in May last year. With this approval, Panion & BF Biotech aims to seize the market opportunity presented by over 100,000 kidney dialysis patients in South Korea. More... (in Chinese)
|Taiwan Precision Health Symposium held, attracting notable scientists from around the world |
3 July, 2023
On July 3rd the Taiwan Precision Health Symposium, organized by the Institute of Biomedical Sciences at Academia Sinica, was held, focusing on the development and application of precision medicine and genomic medicine in Taiwan. Notable participants at the symposium included Maynard Olson, one of the initiators of the Human Genome Project (HGP); Eric Green, Director of the National Human Genome Research Institute (NHGRI) at the US National Institutes of Health (NIH); and John Chambers, Chief Scientist of Precision Health Research in the Singapore National Precision Medicine Program (NPM) and Principal Investigator of the SG100K Research Project. More... (in Chinese)
|Startup Island Taiwan Podcast talks future of health care with Lydia.AI |
3 July, 2023
Technology startup Lydia.AI harnesses artificial intelligence and global health data to create a risk-scoring engine that is able to quantitatively evaluate an individual掇 overall health, per Startup Island Taiwan Podcast. More...
|Bora Pharmaceuticals Partners with Lundbeck in Taiwan |
3 July, 2023
Bora Pharmaceuticals Co., Ltd. today announced its partnership with Lundbeck Export A/S and their portfolio of brain diseases drugs in Taiwan. Under the partnership, Bora will be exclusively responsible for sales and marketing of Lundbeck's products through Bora's specialized hospital, clinic, and drug store channels in Taiwan effective from January 1st, 2024. More...
|Taiwan Bio Industry Organization (Taiwan BIO) |
Contact: Daisy Tsai
Tel: +886 2 27836028 ext 14 FAX : +886 2 27836027
Mobile: +886 933-139647 | Line ID : daisy222
BIO Asia-Taiwan July 26-30, 2023
Taiwan Bio Industry Organization (TBIO)
Room C229, Bldg. C, No.99, Ln. 130, Sec. 1, Academia Rd.,
Nangang Dist., Taipei, Taiwan (11571)